Advertisement

Genzyme, a Sanofi company (NYSE: SNY), reported positive results of the first Phase 3 trial of its therapy for the treatment of Gauchers disease type 1, a rare genetic disease in which the patient does not have the glucocerebrosidase enzyme. Not having the enzyme causes various harmful substances to build up in a person’s liver, spleen, bones, and bone marrow and prevents organs from functioning the correct way.

Advertisement
Advertisement